JNJ-87189401

DRUG3 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Metastatic Castration-resistant Prostatic NeoplasmsProstatic Neoplasms

Phase 1

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

RecruitingNCT06095089

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2023-11-01End: 2028-06-28Target: 355Updated: 2026-08-28

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

RecruitingNCT07082920

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2025-07-07End: 2027-12-30Target: 140Updated: 2026-08-28

Phase 3

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

RecruitingNCT07164443

Janssen Research & Development, LLCMetastatic Castration-resistant Prostatic Neoplasms

Start: 2025-09-02End: 2028-08-18Target: 1203Updated: 2026-08-28

Related Papers

A phase 3 randomized, double-blind, placebo-controlled study of a pasritamig plus best supportive care in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2026-05-28